908 Devices Unveils New Glucose and Lactate On-Line Device for Bioprocess Monitoring and Control

MAVEN offers real-time monitoring without bioreactor volume loss, accelerating process development and optimizing biologics, cell therapy and gene therapy manufacturing

908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced the launch of MAVEN, a device for on-line monitoring and control of glucose and lactate in cell culture and fermentation processes. MAVEN empowers biopharma companies to make timely decisions based on highly sensitive, real-time measurements. Taking measurements as frequently as every two minutes, MAVEN operates without having to manually draw samples out of the bioreactor due to its novel aseptic sampling approach. This improves process understanding, saves operator time and reduces the risk of process contamination--which in turn accelerates development workflows.

For biopharmaceutical process development scientists who seek to optimize cell culture and fermentation processes to improve product yield, quality, efficacy and safety, MAVEN provides highly precise, on-line monitoring of glucose and lactate without any loss of bioreactor volume. This enables real-time control of substrate feeding to maintain optimal nutrient and metabolite concentrations, even at very low levels. MAVEN is used in concert with the company’s REBEL device, an at-line cell culture media analyzer that quantitates over 30 additional key media nutrients in less than 10 minutes.

“While biologics and cell and gene therapies have proven their ability to make huge advances in human health, costs remain high due to time-intensive processes,” said Dr. Wolfgang Künnecke, VP of Bioanalytics R&D, 908 Devices. “We are working diligently to develop solutions to enhance process understanding and aid in control. Specifically for glucose and lactate, we are providing precision measurements that preserve sample integrity and have low limits of detection. Together MAVEN and REBEL can be used to improve and optimize cell culture feeding strategies with clarity, control and ease.”

As an on-line device, MAVEN is a critical part of the bioprocessing workflow. MAVEN is GMP compliant, takes up a small footprint in any lab and is incredibly easy to use. In addition, MAVEN’s ability to precisely monitor concentrations even at very low levels, 0.01 g/L of glucose and 0.05 g/L of lactate, makes it particularly beneficial to cell therapy applications where tight control of cell culture conditions is vital.

“As more advanced therapies enter the pipeline there is an increasing need for simple, automated on-line devices like MAVEN for measuring and monitoring process and product attributes,” said Dr. Kevin J. Knopp, CEO and co-founder, 908 Devices. “MAVEN’s incorporated aseptic sampling probe serves as an interface for future on-line analyzers as we broaden our bioanalytics platform and develop an ecosystem of connected, on-line tools.”

MAVEN is available now worldwide. To learn more, visit www.908devices.com/products/maven or attend our webinar on January 17 at 11 a.m. ET by registering at https://908devices.com/now-starts-now. Additionally, check out 908 Devices at industry events, including Advanced Therapies Week (booth #513) and PepTalk (booth #313).

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005398/en/

MAVEN's incorporated aseptic sampling probe serves as an interface for future on-line analyzers as we broaden our bioanalytics platform and develop an ecosystem of connected, on-line tools.